Cancer Therapeutics: Technology, Discovery, and Targeted Delivery Program

癌症治疗：技术、发现和靶向治疗项目

基本信息

批准号：
10230666
负责人：
CHERYL LYNN WILLMAN
金额：
$ 0.68万
依托单位：
UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR
依托单位国家：
美国
项目类别：
财政年份：
2005
资助国家：
美国
起止时间：
2005-09-26 至 2021-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10230666
关键词：
Advisory Committees Aerosols Animal Model Antibodies Antineoplastic Agents Bacteriophages Biological Biological Assay Biological Models Biology Biomedical Engineering Biotechnology Blood Vessels Cancer Biology Cancer Center Cancer Center Support Grant Cancer Diagnostics Cell Surface Receptors Cells Clinical Clinical Investigator Clinical Trials Clinical Trials Network Collaborations Coupled Critiques Diagnostic Imaging Direct Costs Doctor of Philosophy Drug Delivery Systems Early Intervention Engineering Evaluation Faculty Flow Cytometry Foundations Funding G-Protein-Coupled Receptors Goals Grant Human Hydrogels Image Industry Informatics Infrastructure Integrins Intellectual Property Intervention Intervention Studies Intervention Trial Investigation Isotopes Laboratories Lead Leukocytes Libraries Ligands Malignant Neoplasms Mathematics Methods Mission NCI Center for Cancer Research Nanotechnology Neoplasm Circulating Cells New Mexico Normal Cell Normal tissue morphology Oral Pathologic Pathway interactions Peer Review Peptide antibodies Peptides Phage Display Pharmaceutical Preparations Pharmacologic Substance Pharmacy facility Phase Phase I Clinical Trials Phosphorylation Physicians Population Prediction of Response to Therapy Publications Publishing Research Research Institute Research Personnel Route Scientist Silicon Dioxide Talents Technology Therapeutic Therapeutic Agents Therapeutic Intervention Therapeutic Uses Tissues Translating Translations Tumor Tissue United States National Institutes of Health Universities Virus-like particle Work base cancer cell cancer clinical trial cancer imaging cheminformatics clinical application clinical translation college combinatorial commercialization design drug discovery experience high throughput screening imaging agent in vitro Model in vivo innovation investigator-initiated trial mathematical methods mathematical model medical schools member molecular imaging multidisciplinary nanoGold nanofabrication nanoparticle nanoscience novel pre-clinical programs receptor recruit respiratory response small molecule small molecule inhibitor targeted delivery targeted treatment translational pipeline translational scientist working group

Advisory Committees Aerosols Animal Model Antibodies Antineoplastic Agents Bacteriophages Biological Biological Assay Biological Models Biology Biomedical Engineering Biotechnology Blood Vessels Cancer Biology Cancer Center Cancer Center Support Grant Cancer Diagnostics Cell Surface Receptors Cells Clinical Clinical Investigator Clinical Trials Clinical Trials Network Collaborations Coupled Critiques Diagnostic Imaging Direct Costs Doctor of Philosophy Drug Delivery Systems Early Intervention Engineering Evaluation Faculty Flow Cytometry Foundations Funding G-Protein-Coupled Receptors Goals Grant Human Hydrogels Image Industry Informatics Infrastructure Integrins Intellectual Property Intervention Intervention Studies Intervention Trial Investigation Isotopes Laboratories Lead Leukocytes Libraries Ligands Malignant Neoplasms Mathematics Methods Mission NCI Center for Cancer Research Nanotechnology Neoplasm Circulating Cells New Mexico Normal Cell Normal tissue morphology Oral Pathologic Pathway interactions Peer Review Peptide antibodies Peptides Phage Display Pharmaceutical Preparations Pharmacologic Substance Pharmacy facility Phase Phase I Clinical Trials Phosphorylation Physicians Population Prediction of Response to Therapy Publications Publishing Research Research Institute Research Personnel Route Scientist Silicon Dioxide Talents Technology Therapeutic Therapeutic Agents Therapeutic Intervention Therapeutic Uses Tissues Translating Translations Tumor Tissue United States National Institutes of Health Universities Virus-like particle Work base cancer cell cancer clinical trial cancer imaging cheminformatics clinical application clinical translation college combinatorial commercialization design drug discovery experience high throughput screening imaging agent in vitro Model in vivo innovation investigator-initiated trial mathematical methods mathematical model medical schools member molecular imaging multidisciplinary nanoGold nanofabrication nanoparticle nanoscience novel pre-clinical programs receptor recruit respiratory response small molecule small molecule inhibitor targeted delivery targeted treatment translational pipeline translational scientist working group

展开

项目摘要

CANCER THERAPEUTICS: TECHNOLOGY, DISCOVERY & TARGETED DELIVERY (CT) RESEARCH PROGRAM ABSTRACT The Cancer Therapeutics: Technology, Discovery and Targeted Delivery (CT) Research Program, led by Larry A. Sklar, PhD and Renata Pasqualini, PhD, consists of a multidisciplinary team of 43 (27 full and 16 associate members) of basic, translational and clinical investigators assembled from 5 Departments in the UNM School of Medicine, 2 in the UNM College of Engineering, the UNM College of Pharmacy, New Mexico State University, and our UNM Cancer Center (UNMCC) consortium partners: Lovelace Respiratory Research Institute (LRRI) and Sandia (SNL) and Los Alamos National (LANL) Laboratories. CT is a new UNMCC Research Program, developed through rigorous program planning and evaluation in response to the prior 2010 NCI CCSG critique and guidance from the External Advisory Committee (EAC). Building from its origins in the Cancer Biotechnology component of the former Cancer Biology & Biotechnology Program, CT has retained and acquired scientific expertise in small molecule discovery and drug repurposing, combinatorial targeting of peptide and antibody phage display libraries, nanoparticle and virus-like particle (VLP)-based drug delivery, as well as imaging and isotopes. During the prior funding period (from 1/1/10 to 9/1/2014), CT program members published 336 original peer-reviewed articles and reviews (37% intra-programmatic and 24% inter-programmatic) and participated in 6 investigator-initiated trials. As of 9/1/14, CT funding is $16,076,676 in annual direct costs, of which $14,196,182 is peer-reviewed direct funding and $3,105,330 is from the NCI. Dr. Sklar is an expert in leukocyte biology and drug discovery and/or repurposing while Dr. Pasqualini is an expert in vascular targeting whose pivotal work in vivo with phage display has led to extensive pre-clinical and clinical applications; both leaders are experienced in translation and commercialization. CT has contributed to the bulk of UNMCC intellectual property as well as 10 biotechnology or pharmaceutical start-up companies. The Program benefits from the technological expertise in partnerships among the UNMCC, LRRI, SNL and LANL. Through the strategic recruitment of new talented faculty and infrastructure reorganization, the CT translational pipeline is expanding through: i) small molecule discovery and drug repurposing, flow cytometry technology and cheminformatics; ii) combinatorial targeting through selection of peptide and antibody phage display libraries; iii) targeted ligand-directed delivery coupled to material nanofabrication, predictive mathematical methodology, and molecular imaging; and iv) early translation into clinical application. Noted multidisciplinary, multi-investigator programmatic grants held by CT members include large NIH, NCI and DOD funds supporting translational investigations and clinical interventions. Recent physician-scientist and clinical investigator recruits will lead the current and planned portfolio of early investigator-initiated clinical trials. CT's overall goal is to discover, develop and translate innovative platform technologies into cancer diagnostic and therapeutic applications by using bioengineering, biotechnology, nanotechnology, phage display, mathematics and informatics as the basis for early interventional clinical trials.

癌症治疗学：技术，发现和目标交付（CT）研究计划抽象的癌症治疗学：技术，发现和目标交付（CT）研究计划，由拉里领导 A. Sklar博士和Renata Pasqualini博士，由43人组成的多学科团队（27个完整和16名合伙人基本，转化和临床研究人员的成员来自UNM学校的5个部门医学，新墨西哥州大学UNM药学院UNM工程学院2 以及我们的UNM癌症中心（UNMCC）财团合作伙伴：Lovelace呼吸研究所（LRRI）和Sandia（SNL）和Los Alamos National（Lanl）实验室。 CT是一个新的UNMCC研究计划，通过严格的计划计划和评估来响应于2010年之前的NCI CCSG批评和外部咨询委员会（EAC）的指导。起源于癌症生物技术前癌症生物学与生物技术计划的组成部分，CT保留并获得了科学小分子发现和药物重新利用的专业知识，肽和抗体的组合靶向噬菌体显示库，纳米颗粒和病毒样颗粒（VLP）的药物输送以及成像和成像同位素。在以前的资金期（从1/1/10到9/1/2014）中，CT计划成员发布了336个原始同行评审的文章和评论（37％概括性内部图和24％的程序间截图），参与6 研究人员发动的试验。截至14年9月1日，CT资金为$ 16,076,676，每年直接费用，其中14,196,182美元是由同行评审的直接资金，3,105,330美元来自NCI。 Sklar博士是白细胞生物学专家 pasqualini博士是血管靶向的专家，其关键在带有噬菌体显示的体内导致了广泛的临床和临床应用。两位领导人都经验丰富在翻译和商业化中。 CT为大部分UNMCC知识产权以及 10个生物技术或制药初创公司。该计划受益于技术专业知识在UNMCC，LRRI，SNL和LANL之间的合作伙伴关系中。通过战略招募新才华横溢的教师和基础设施重组，CT翻译管道正在扩展：i）小分子发现和药物重新利用，流式细胞仪技术和化学信息学； ii）组合靶向通过选择肽和抗体噬菌体显示库； iii）针对的配体定向递送耦合到材料纳米化，预测性数学方法论和分子成像；和iv）早期翻译进入临床应用。著名的CT成员持有的多学科的多学科的多项式程序化赠款包括大型NIH，NCI和DOD资金，支持翻译调查和临床干预措施。最近的医师科学家和临床研究者的新兵将领导早期的当前和计划组合研究者发射的临床试验。 CT的总体目标是发现，开发和翻译创新平台通过使用生物工程，生物技术，用于癌症诊断和治疗应用的技术纳米技术，噬菌体显示，数学和信息学作为早期介入临床试验的基础。